Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Terminated 1Recruiting 1Completed 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Endocrine 5NET 3Gastrointestinal 2

Conditions

Neuroendocrine Tumors 14Gastro-enteropancreatic neuroendocrine tumor 4Carcinoid Tumor 3Serotonin Syndrome 1Neuroendocrine Tumors in Lung 1Neoplastic Cells, Circulating 1Gastrointestinal Neoplasms 1Flushing 1Diarrhea 1Carcinoma, Hepatocellular 1Adenoma, Islet Cell 1Acromegaly 1

Interventions

Everolimus 8lanreotide 3gallium Ga 68 dotatate 3Octreotide 3Nivolumab 3pasireotide 2lutetium Lu 177 dotatate 2cabozantinib 2Temozolomide 2Sunitinib 2Ga(III)-DOTATOC 2Erlotinib Hydrochloride 2Capecitabine 2zimberelimab 1veliparib 1telotristat ethyl 1recombinant interferon alpha 2b-like protein 1pertuzumab 1pembrolizumab 1olaparib 1nintedanib 1ibrutinib 1ganitumab 1fosbretabulin 1epothilone B 1cixutumumab 1arginyllysine 1TKM-080301 1Sorafenib 1Serotonin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Carcinoid Tumor × lanreotide × NET × Clear all
NCT05477576 2026-03-30

ACTION-1

RayzeBio, Inc.

Phase 3 Recruiting
338 enrolled
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Carcinoid Tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

NCT02859064 2023-12-05

Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres

SCRI Development Innovations, LLC

Phase 2 Terminated
6 enrolled 12 charts
EndocrineGastrointestinalNET

Carcinoid Tumor, Gastrointestinal Neoplasms, Neuroendocrine Tumors

NCT00774930 2022-10-14

ELECT

Ipsen

Phase 3 Completed
115 enrolled 17 charts
EndocrineNET

Carcinoid Tumor, Diarrhea, Flushing, Neuroendocrine Tumors, Serotonin Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡